Genzyme Archives -

Sanofi has claimed approval in the EU for Xenpozyme as a treatment for acid sphingomyelinase deficiency (ASMD) –

Celebrations for ASMD community as EU clears Sanofi’s Xenpozyme

https://pharmaphorum.com/news/celebrations-for-asmd-community-as-eu-clears-sanofis-xenpozyme/

CHMP backs Sanofi’s Xenpozyme as first drug for ASMD

Phil Taylor alopecia, EigerBio, Eli Lilly, Genzyme, Olumiant, progeria, rare disease, Sanofi, Xenpozyme, Zokinvy 0 Comment

Sanofi’s Genzyme unit has moved a step closer to securing EU approval for Xenpozyme – its enzyme replacement

CHMP backs Sanofi’s Xenpozyme as first drug for ASMD

https://pharmaphorum.com/news/chmp-backs-sanofis-xenpozyme-as-first-drug-for-asmd/

Oncology/ Views & Analysis/ Views and analysis

Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexit

Richard Staines Brexit, cancer, Genzyme, Marc Moodley, NICE, Sanofi, Sanofi Genzyme 0 Comment

Marc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for

Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexit

https://pharmaphorum.com/views-analysis-oncology/sanofi-genzyme-uk-medical-boss-marc-moodley-discusses-oncology-plans-nice-and-brexit/

News

Sanofi settles dispute with Genzyme investors over MS drug

Richard Staines Genzyme, litigation, multiple sclerosis, Sanofi 0 Comment

Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately

Sanofi settles dispute with Genzyme investors over MS drug

https://pharmaphorum.com/news/sanofi-settles-dispute-with-genzyme-investors-over-ms-drug/

News

Sanofi Q1 growth driven by Genzyme

George Underwood Genzyme, Q1, results, Sanofi 0 Comment

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit,

Sanofi Q1 growth driven by Genzyme

https://pharmaphorum.com/news/sanofi-q1-growth-driven-by-genzyme/

News/ News/ R&D

Sanofi and Alnylam conclude research phase of RNAi alliance

George Underwood Alnylam, Genzyme, RNAi, Sanofi 0 Comment

Sanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance

Sanofi and Alnylam conclude research phase of RNAi alliance

https://pharmaphorum.com/news/sanofi-and-alnylam-conclude-research-phase-of-rnai-alliance/

News/ News/ Sales and Marketing

Sanofi expects growth as rare disease drugs boost earnings

George Underwood financial results, Genzyme, Q4, Sanofi 0 Comment

Sanofi’s strategy of betting on new drugs and biotech acquisitions seems to be paying off, as the company

Sanofi expects growth as rare disease drugs boost earnings

https://pharmaphorum.com/news/sanofi-expects-growth-as-rare-disease-drugs-boost-earnings/

News

Sanofi beats expectations, driven by rare diseases and vaccines

Richard Staines Dupixent, Genzyme, Lantus, Sanofi, Sanofi-Pasteur 0 Comment

But sales of key insulin fall amid biosimilar competition.

Sanofi beats expectations, driven by rare diseases and vaccines

https://pharmaphorum.com/news/sanofi-beats-expectations-driven-rare-diseases-vaccines/

News/ US

Vericel hopes for US hit with Maci knee treatment

Richard Staines advanced therapies, Genzyme, pricing, reimbursement, sales, Sanofi 0 Comment

Tissue engineering product previously flopped in EU.

Vericel hopes for US hit with Maci knee treatment

https://pharmaphorum.com/transversal-categories/us/vericel-hopes-us-hit-maci-knee-treatment/

Trending

Genzyme

Login